Sign In
Buy SRPT
$14.86
-0.700 (-4.50%)
At Close: Jul 31, 2026
Sarepta Therapeutics pops as results top estimates and Morgan Stanley raises share price to $187
12:46pm, Wednesday, 01'st Mar 2023
Sarepta Therapeutics Inc (NASDAQ:SRPT) stock rocketed after the drug company posted fourth quarter financial results that topped Wall Street estimates and Morgan Stanley (NYSE:MS) said the stock could
Sarepta Rockets And Breaks Out As FDA Smooths The Path For Its Gene Therapy
10:01am, Wednesday, 01'st Mar 2023
Sarepta could snag an accelerated approval for its muscular dystrophy gene therapy, analysts suggested Wednesday as SRPT stock rocketed. The post Sarepta Rockets And Breaks Out As FDA Smooths The Path
Why Is Sarepta Therapeutics (SRPT) Stock Up 21% Today?
09:49am, Wednesday, 01'st Mar 2023
Sarepta Therapeutics (NASDAQ: SRPT ) stock is heading higher on Wednesday following the release of its latest earnings report. For the fourth quarter of 2022, Sarepta Therapeutics reported adjusted ea
Investors Just Hit the Jackpot on These 2 Nasdaq Biotech Stocks
09:09am, Wednesday, 01'st Mar 2023
Markets are trying to rise, and these companies are helping out.
Sarepta Therapeutics, Inc. (SRPT) Q4 2022 Earnings Call Transcript
09:56pm, Tuesday, 28'th Feb 2023
Sarepta Therapeutics, Inc. (NASDAQ:SRPT ) Q4 2022 Earnings Conference Call February 28, 2023 4:30 PM ET Company Participants Mary Jenkins - Senior Manager of Investor Relations Doug Ingram - President
Sarepta Therapeutics (SRPT) Reports Q4 Loss, Tops Revenue Estimates
09:05pm, Tuesday, 28'th Feb 2023
Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of 3.12% and 3.63%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Sarepta stock surges more than 10% as results top expectations, drug given priority review
04:45pm, Tuesday, 28'th Feb 2023
Sarepta Therapeutics Inc. SRPT shares rallied in the extended session Tuesday after the biotech drug maker topped Wall Street expectations, and said U.S. regulators granted a priority review status fo
7 Biotech Stocks That Will Make You Rich in 10 Years
03:44pm, Wednesday, 18'th Jan 2023
If you have the patience to go through wild undulations, then you may be a candidate for biotech stocks that will make you rich in 10 years. Even among the most established biotechnology firms, they'r
Sarepta: Raised Financial Guidance, Looming Catalyst Makes This Worth A Look
12:17pm, Tuesday, 17'th Jan 2023
Sarepta Therapeutics, Inc. net product revenues for Q4 2022 are expected to come in about 32% higher at $235.5 million; Financial results for Q4 2022 are expected late February 2023. BLA of SRP-9001 f
2 Under-the-Radar Biotech Stocks to Buy in 2023
08:45am, Friday, 06'th Jan 2023
These biotechnology stocks are pushing ahead with promising innovations.
Sarepta Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
08:30am, Tuesday, 03'rd Jan 2023
CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will pr
2 Top Healthcare Stocks to Buy for the Long Haul
02:53pm, Friday, 09'th Dec 2022 The Motley Fool
These two companies are just getting started.
Sarepta Therapeutics (SRPT) Up 17.1% Since Last Earnings Report: Can It Continue?
04:31pm, Friday, 02'nd Dec 2022 Zacks Investment Research
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Sarepta Therapeutics (SRPT) Up 17.1% Since Last Earnings Report: Can It Continue?
12:48pm, Friday, 02'nd Dec 2022
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock?
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11:00pm, Wednesday, 30'th Nov 2022 GlobeNewswire Inc.
CAMBRIDGE, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on November 30, 2022 t
